Experienced in Angiosarcoma of the Scalp

Kristof Cuppens

't Hasselt, VLG, BE 
Experienced in Angiosarcoma of the Scalp
't Hasselt, VLG, BE 
OverviewLocationsClinical Research

Overview

Kristof Cuppens practices in 't Hasselt, Belgium. Mr. Cuppens is rated as an Experienced expert by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Angiosarcoma of the Scalp, EGFR Positive Lung Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Angiosarcoma of the Scalp.

Gender
Male

Locations

't Hasselt, VLG, Belgium
Other Locations
Diepenbeek, VLG 3590, Belgium
Leuven, VLG 3000, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3

26 Total Publications

Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.
Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.
Journal: ESMO open
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cuppens's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile